Conference Reports for NATAP

Back

EASL - European Association for the Study of the Liver Barcelona, Spain May 27-30, 2026     The potentially best-in-class HBV ASO ALG-170674 demonstrates additive to synergistic antiviral activities when combined with other anti-HBV modalities - (06/14/26)   AASLD-EASL Zone ALT Associated with Higher Risk of HCC and Liver-Related Mortality in Chronic Hepatitis B Patients - (06/14/26)   Sustained reduction of HBV antigen levels at ≥6 months follow-up in HBeAg-positive participants with chronic hepatitis B infection after 96 weeks of 300 mg pevifoscorvir sodium monotherapy - (06/14/26)   PEVIFOSCORVIR SODIUM DEMONSTRATES PROFOUND ANTIVIRAL ACTIVITY IN UNTREATED HBeAg POSITIVE SUBJECTS, REGARDLESS OF BASELINE ALT LEVEL - (06/14/26)   Potent and durable off-treatment reduction of HBsAg levels and cccDNA-derived transcripts by the CAM-E ALG-001075 in cellbased experiment - (06/14/26)   Factors Associated With Lack of Alanine Aminotransferase Normalisation in Patients With Chronic Hepatitis B Virus After 8 Years of Tenofovir-Based Treatment - (06/14/26)   Transcriptomic Profiling Reveals Distinct Immune Signatures in Chronic Hepatitis B and Identifies Blood Transcriptional Modules Associated With Hepatitis B e Antigen Loss Following Therapeutic Vaccination With GS-2829 and GS-6779 - (06/14/26)   Baseline and On-Treatment Characteristics of HBeAg-Positive Patients and Correlates of HBeAg Loss Following GS-2829 and GS-6779 Therapeutic Vaccination in Virally Suppressed Patients With Chronic Hepatitis B - (06/14/26)   Sequential Combination of Antisense Oligonucleotide AHB-137 Followed by HBV Vaccine Leads to HBsAg Loss and Seroconversion in the AAV-HBV Mice - (06/14/26)   Synergistic Effect of Diabetes and Hypertension on the Risk of Liver Disease Progression in Hepatitis B Virus Infection - (06/14/26)   Antisense oligonucleotide-based strategy to target hepatitis delta virus infections - (06/14/26)   Safety, Pharmacokinetics, and Pharmacodynamic Activity of ABI-6250, a First-in-Class Oral Hepatitis D Virus Entry Inhibitor in Healthy Subjects: Interim Results From a Randomized, Blinded, Phase 1a Study - (06/13/26)   Senolytics dasatinib and quercetin reduce fibrosis in metabolic dysfunction-associated steatohepatitis: The Truth Study - (06/12/26)   PBC Saroglitazar Phase 2b/3 EPICS I - (06/12/26)   Viral Hepatitis Debrief EASL 2026, Prof Markus Cornberg - (06/12/26)   Virological breakthroughs during long-term Bulevirtide monotherapy in patients with CHD: integrated analysis from the multicenter real-life save-d and d-shield studies - (06/12/26)   Antiviral therapy based on the EASL guideline 2025 reduces the risk of hepatocellular carcinoma: a multinational study - (06/12/26)   Safety, tolerability, pharmacokinetics, and pharmacokinetics of GSK3965193 in patients with chronic hepatitis B (CHB) - (06/12/26)   Antiviral therapy based on the EASL guideline 2025 reduces the risk of hepatocellular carcinoma: a multinational study - (06/12/26)   Up to 36 months durability of functional cure in response to bepirovirsen therapy in B-Clear On-NA responders: Results from the B-Sure study - (06/12/26)   Up to 36 months durability of functional cure in response to bepirovirsen therapy in B-Clear Not-on-NA responders: Results from the B-Sure study - (06/12/26)   Low HBsAg and HBV DNA levels lead to stable state of sustained control among chronic hepatitis B patients: Results from the SIGNAL study - (06/12/26)   Long-term clinical outcomes in chronic hepatitis B patients with nucleos(t)ide analogue treatment who achieved HBsAg <100 IU/mL - (06/12/26)   Prevalence and Impact of Hepatic Steatosis on Clinical Outcomes in a U.S. Multi-Ethnic Cohort of Chronic Hepatitis B - (06/12/26)   Management of chronic hepatitis B in people with human immunodeficiency virus infection in Europe: real-world evidence from Spain and Germany - (06/12/26)   Machine Learning Models of Non-invasive Tests to Predict MASH and Fibrosis Stage Based on MAESTRO-NAFLD-1 and MAESTRO-NASH Liver Biopsies - (06/11/26)   In F0-F1 and F2-F3 MASH, ≥ 5% weight loss significantly lowers VCTE and ELFTM independent of biopsy fibrosis improvement; resmetirom and not placebo reduction of ELF and VCTE are associated with biopsy improvement of fibrosis, independent of weight loss - (06/11/26)   Baseline ANTICIPATE score and response predicts liver outcome events in a 180 patient MASH cirrhosis cohort treated with resmetirom - (06/11/26)   Early and Week 52 biomarker (MRI-PDFF, ALT, MRE and PRO-C3) responses to resmetirom predict improvements in MASH and liver fibrosis - (06/11/26)   Reducing CV risk in patients with MASH independent of baseline statin use: Lp(a) and LDL-C lowering by resmetirom - (06/11/26)   Dissecting the alternate mediterranean diet score identifies whole grains and red meat as key determinants of fibrosis risk in MASLD...'red/processed meat increased of significant & advanced fibrosis' - (06/11/26)   Bemnifosbuvir and ruzasvir administered as a fixed-dose combination has low potential to inhibit P-gp, BCRP or OATP1B1/3 mediated transport - (06/10/26)   Proton-pump inhibitor omeprazole did not affect the plasma pharmacokinetics of bemnifosbuvir and ruzasvir fixed-dose combination in healthy participants - (06/10/26)   24-Week Safety and Efficacy of Brelovitug Monotherapy for the Treatment of Chronic Hepatitis D: Data From Phase 2b of AZURE-1 - (06/08/26)   Real-world outcomes in patients with primary biliary cholangitis who initiated elafibranor treatment with baseline alkaline phosphatase levels between 1× to 1.67× the upper limit of normal - (06/08/26)   Biochemical response is associated with liver stiffness stability in patients with primary biliary cholangitis treated with seladelpar for up to 3 years in the ongoing open-label ASSURE study - (06/08/26)   Seladelpar Effect on Lipids and Muscle Safety With Concomitant Statin Use in Patients With Primary Biliary Cholangitis: Interim Results From the Open-Label ASSURE Study With up to 4 Years of Treatment - (06/08/26)   Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Cirrhosis, Including Those With Clinical Signs of Portal Hypertension: Interim Results From the Open-Label ASSURE Study With up to 4 Years of Treatment - (06/08/26)   Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Risk Factors for Progression Including Younger Age at Diagnosis or Higher Liver Stiffness in the Pivotal RESPONSE Study - (06/08/26)   Sustained Alkaline Phosphatase Normalisation and Biochemical Response Are Associated With Reduced Disease Progression and Clinical Outcomes Among Adults Prescribed Ursodeoxycholic Acid for Primary Biliary Cholangitis - (06/08/26)   Efficacy and safety of seladelpar in patients with primary biliary cholangitis and alkaline phosphatase levels between 1 and 1.67 × upper limit of normal: interim results from the open-label ASSURE study - (06/08/26)   Seladelpar vs Elafibranor as second-line treatments for primary biliary cholangitis: asystematic review and meta-analysis - (06/08/26)   Sustained Alkaline Phosphatase Normalisation and Biochemical Response Are Associated With Reduced Disease Progression and Clinical Outcomes Among Adults Prescribed Ursodeoxycholic Acid for Primary Biliary Cholangitis - (06/08/26)   Long-term treatment with elafibranor improves markers of immune response and inflammation in primary biliary cholangitis - (06/08/26)   Long-term improvements in lipid profiles with elafibranor treatment, and favourable safety with concomitant statin use, in patients with primary biliary cholangitis during the open-label extension of the phase III ELATIVE® trial - (06/08/26)   Factors Associated With Second-Line Treatment Initiation Among Real-World, Second-Line-Eligible Patients With Primary Biliary Cholangitis in the United States - (06/08/26)   Lower Healthcare Resource Utilisation and Costs Associated With Alkaline Phosphatase Normalisation and Composite Biochemical Response Among Adults Prescribed Ursodeoxycholic Acid for Primary Biliary Cholangitis - (06/08/26)   Linafexor in UCDA-inadequate PBC: A phase 2 trial of a pulsatile FXR agonist - (06/08/26)   Safety and efficacy of permafibrate (K-808), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with primary biliary cholangits: twelve-week data from the randomized, placebo-controlled, PEMA-PBC Dose-finding study - (06/08/26)   Management of patients with primary Biliary cholangitis in the post-obeticholic acid era: first real-world effectiveness data on Elafibranor and Seladelpar from the COLHai registry - (06/08/26)   Characteristics and Treatment Patterns of Primary Biliary Cholangitis: Real-World Insights From a Linked Claims-Electronic Medical Records Database - (06/08/26)   Second-line treatment with novel PPAR agonists in patients with primary biliary cholangitis: Real-world experience from a European tertiary care center - (06/08/26)   Efficacy and Safety of Seladelpar vs Placebo in Patients With Primary Biliary Cholangitis and Metabolic Syndrome in the Pivotal Phase 3 RESPONSE Study - (06/08/26)   Meaningful Within-Patient Change on the 5-D Itch Scale in Patients With Primary Biliary Cholangitis Experiencing Pruritus - (06/08/26)   Real-world experience with seladelpar in primary biliary cholangitis: first results from the Italian RESTART-PBC study - (06/08/26)   Linafexor in UCDA-inadequate PBC: A phase 2 trial of a pulsatile FXR agonist - (06/08/26)   Real-world effectiveness and safety of seladelpar in primary biliary cholangitis: a nationwide electronic health record-based study - (06/08/26)   Elafibranor treatment results in rapid reductions in biochemical markers and symptom burden in real-world practice: Interim results from the prospective, non-interventional ELFINITY phase IV global study in patients with primary biliary cholangitis - (06/08/26)   Navigating hepatitis C (HCV) treatment decision-making during pregnancy: a qualitative study - (06/03/26)   Is undetectability of HDV RNA for 96 weeks of Bulevirtide associated with a sustained virological response off-treatment in the real-life ? Results from the French ANRS/MIE HD EP 01 HEPDELTA Cohort better resolution - (06/03/26)   Prevalence and socioeconomics of hepatitis D virus coinfection in two Southern California counties - (06/03/26)   LONG-TERM VIROLOGICAL AND CLINICAL OUTCOMES IN PATIENTS WITH HDV-RELATED CIRRHOSIS TREATED WITH BULEVIRTIDE MONOTHERAPY FOR UP TO 4 YEARS (SAVE-D STUDY) better resolution - (06/02/26)   Women's perspectives on care barriers in the setting of untreated HCV - (06/02/26)   Survival benefits of SVR across different BCLC stages in HCV patients: results from the England National HCV Registry - (06/02/26)   Progress Towards Hepatitis C Virus Elimination in English Prisons -7 Year Outcomes on a Multi-stakeholder Project - (06/02/26)   Hepatic and extrahepatic malignancies in hepatitis C virus-infected patients with cirrhosis treated with direct-acting antivirals in long-term observation - (06/02/26)   HCV screening and prevalence among children with neonatal abstinence syndrome and their mothers - underserved at-risk populations in the era of HCV elimination - (06/02/26)   Trends in Hepatocellular Carcinoma and Mortality Following Hepatitis C Virus Infection in Sweden: Progress Toward the WHO Elimination Goals - (06/02/26)   Impact of Sustained Virological Response on the Prognosis of Patients with HCV-Related Cirrhosis: A Large-Scale Multicenter Cohort Study from the Pre- and Post-DAA Eras - (06/02/26)   From cure to complexity: post-SVR liver and metabolic trajectories in diabetic patients - (06/02/26)   A single VRON-0200 prime dose, followed by a monthly antiviral combination regimen, resulted in rapid, profound, and durable HBsAg declines in chronically hepatitis B infected patients - (06/02/26)   Association of a Liver Steatosis-related Polygenic Risk Score with Hepatocellular Carcinoma Risk after Hepatitis C Virus Eradication - (06/02/26)   Impact of metabolic dysfunction associated steatotic liver disease on hepatocellular carcinoma risk in patients with chronic hepatitis B or chronic hepatitis C: a nationwide cohort study - (06/02/26)   Prevalence and Impact of Hepatic Steatosis on Clinical Outcomes in a U.S. Multi-Ethnic Cohort of Chronic Hepatitis B - (06/02/26)   Abbreviated gadoxetic acid-enhanced magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance in high-risk patients: a randomized controlled trial - (06/01/26)   HCV screening and prevalence among children with neonatal abstinence syndrome and their mothers - underserved at-risk populations in the era of HCV elimination - (06/01/26)   Prevalence of advanced fibrosis and cirrhosis amongst patients with hepatitis C in a UK prison - (06/01/26)   Scaling up ProLINK nationwide in Spain, early results of an implementation strategy for hepatitis C and hepatitis B and delta virus search and linkage to care - (06/01/26)   EPIDEMIOLOGY OF HEPATITIS DELTA VIRUS IN BELGIUM: A PROSPECTIVE CROSS-SECTIONAL COHORT Study - (06/01/26)   Lonafarnib/ritonavir with or without peginterferon achieves rapid, durable responses in a chronic hepatitis D: extended analyses from the phase 3 D-LIVR trialt - (06/01/26)   Hepatitis delta in Spain: prevalence and clinical, demographic and virological characterization from a nationwide prospective cohort - (06/01/26)   Long-Term Virological and Clinical Outcomes in Patients with HDV-Related Cirrhosis with Bulevirtide Monotherapy for Up To 4 Years (SAVE-D Study) - (05/29/26)   Is Undetectability of HDV RNA for 96 Weeks of Bulevertide associated with a sustained virological response off-treatment in the real-life ? Results from the French ANRS/MIE HD 01 HEPDELTA Cohort - (05/29/26)   Efficacy and Safety of Tobevibart (VIR-3434) Alone or in Combination With Elebsiran (VIR-2218) in Participants With Chronic Hepatitis Delta Virus Infection: Week 96 Endpoint Analysis From the Phase 2 SOLSTICE Trial - (05/29/26)   The New EASL treatment indications for HBeAg-negative chronic hepatitis B virus infection reduce grey-zone patients and reflect better routine clinical practice - (05/28/26)   Enhancing Effects of Combining Resmetirom and Semaglutide in a Modified AMLN Diet-induced Mouse Model for Metabolic Dysfunction-associated Steatohepatitis (MASH) - (05/28/26)   Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 - (05/28/26)   Clinically meaningful rates of functional cure in virologically suppressed patients with chronic hepatitis B infection treated with bepirovirsen: B-Well Phase 3 Trials - (05/28/26)   Phase 3 Results of Bepirovirsen HBV - (05/28/26)   Safety and Efficacy of Long-Term Tenofovir Alafenamide Treatment in Patients Aged 60 Years and Older With Chronic Hepatitis B: Experience From Two Phase 3 Clinical Trials - (05/28/26)   Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B - (05/28/26)   Predictors of Advanced Liver Disease Events Among Individuals With Hepatitis Delta Virus Infection in a Large United States Administrative Claims Dataset: A Machine Learning Analysis - (05/28/26)   Impact of Bulevirtide Treatment on Patient-Reported Outcomes Among Patients With Hepatitis Delta in Europe - (05/28/26)   Safety of Bulevirtide 10 mg Is Consistent Across Demographic and Clinical Subgroups: Results From an Integrated Analysis - (05/27/26)   Integrated Efficacy Analysis of Bulevirtide 10 mg From Studies MYR204 and MYR301 at Weeks 48 and 96 Across Subgroups - (05/27/26)   Bulevirtide Monotherapy is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 96 - (05/27/26)   Association of HDV RNA levels with liver disease progression in a large cohort of treatment-naïve Asian patients with chronic hepatitis D - (05/27/26)   HIGH BURDEN OF HEPATIC STEATOSIS, FIBROSIS, AND CARDIOMETABOLIC RISK IN HIV-MONOINFECTED ADULTS ON ANTIRETROVIRAL THERAPY: STEAT-HIV RESULTS - (05/27/26)   HCV exposure modifies MASLD trajectories in people living with HIV: impaired steatosis and persistently elevated liver stiffness despite sustained virologic response - (05/27/26)   Cardiometabolic risk factors and fibrosis in MASLD: comparison between people living with HIV and the general population in Egypt - (05/27/26)   Real-World HCV Epidemiology Data to Drive Elimination Strategies in South Africa - (05/27/26)   Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with impaired health-related quality of life in people with HIV - (05/27/26)   Post-transplant comorbidities, MASLD development and longterm survival in liver recipients with and without HIV infection - (05/27/26)   Sustained Virologic Response Rates Following Incomplete Direct-Acting Antiviral Therapy for Hepatitis C: A Real World Study - (05/27/26)   Modeling the Effect of Long-Acting Injectables of DAA Therapy to Reach HCV Elimination among PWID - (05/27/26)   Treatment of Hepatitis C in Pregnancy with Sofosbuvir/Velpatasvir: Interim results from the STORC study - (05/27/26)   Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 - (05/14/26)